China has been the subject of much debate throughout the manufacturing industry as more companies have considered it an option for reducing costs. However, quality concerns and increasing economic factors have caused some to rethink this outsourcing strategy. In this month's Perspectives feature, industry leaders share their thoughts on whether China remains a viable option for medical device manufacturers or if business will relocate elsewhere.
How will changing economic factors in China impact the trend to outsource there and will that mean a return of industry to the U.S. or growth elsewhere?
Asia Pacific Manager, Omnetics
We must also expect China to venture more into the design side of medical device manufacturing. They will no longer just be a cheap manufacturing source. China will become more vertically integrated on the design side. The world leaders in medical design—U.S., Germany, and Japan—will have to stay on the cutting edge of technology to survive this formidable new competitor.
Component companies in the United States interested in selling products into the Chinese medical market need to understand the dynamics involved. In the United States, private venture capital funds medical start-ups. In China, on the other hand, design is driven by government money. When searching for design engineers in China, look towards the universities such as Shanghai Jiaotong, Tsinghua, and Fuijian Medical University.
The new world economy is bringing major change to the face of the medical market. The boom in China has slowed and their focus is shifting. Other emerging markets are at various stages in their development. India is experiencing the kind of growth China had 10 years ago and many South American countries are on the verge of becoming major players in the medical market.
President and Founder, China Array Plastics LLC
The key issue affecting outsourcing to China is quality control—specifically consistent quality control. The recent milk scandal, following on the heels of scandals in toothpaste, dog food, lead paint in toys, etc., creates anxiety for companies outsourcing to China, and seems to be an entrenched problem in the Chinese supply chain. In each of the aforementioned cases, it was a single link in the supply chain that created the problem with devastating effect across entire industries. The question for a firm sourcing in China becomes how to ensure the integrity of not just its direct supplier, but the sub-suppliers it deals with. Implementing this type of vertical QC program across multiple companies is a difficult and expensive challenge.
Therefore, it is quality control concerns, not economics, that will drive some countries back to the U.S. for sourcing. With the gap between the euro and the dollar starting to look more permanent, European firms are finding the U.S. to be a good compromise between lowering costs and ensuring quality. Other Asian countries probably will not benefit from China’s quality control scandals—Japan and Taiwan because they are too expensive; Vietnam and Thailand because they have unreliable quality control systems as well.
Multinationals and large OEMs that can impose strict quality control on the entire supply chain in China will continue to benefit from the lower cost production available there.
President, InterTech Development Company
Actually, InterTech’s services to create turnkey assembly and test solutions—for both leak testing and functional testing—are in growing demand for companies using the globally-distributed manufacturing model that have or are building Chinese production facilities. Rising wage scales in China are adding to the existing problems of rapid worker turnover, which in turn, create a need for our type services. Engineers with trouble shooting ability are in very short supply in China, and they tend to move from place to place. InterTech’s global response team is helping companies with Chinese facilities involved in test-intensive assembly operations get the Gauge R&R they need, despite this turnover.
In the longer term, we do expect that the move to Chinese production facilities will level off, but that this will not likely spell a return to the U.S. for manufacturing. Rather, one can expect Vietnam and India to take off where Chinese production leaves off.
Vice President, International Market Development, GW Plastics Inc.
GW Plastics has seen steady growth since the company was founded in 1955. While direct costs are rising, the level of technology, market size and productivity are also rising. We do not see a return to U.S. manufacturing as a trend but we do see a continued increase in the complexity and sophistication of the products that are manufactured in the U.S. At the same time, it’s fair to say that market growth in China may be somewhat slowed by concerns about intellectual property protection, environmental problems, human rights issues, as well as the recent quality control issues that have been widely publicized.
GW Plastics, with manufacturing facilities in North America, Mexico, and China, has seen some lower technology, high labor activities flee China for even lower cost regions, but does not see a significant shift now or on the horizon. We do not see a trend of manufacturing returning to U.S. but increasing transportation costs may slow the shift to Asia in the future.
Vice President and Sales Manager, Peridot Corp.
So in the short term, I feel the U.S. and Europe will continue to be looked upon as the place for medical device manufacturers to source critical work. For now, any consideration of outsourcing to China must be carefully weighed against the travel costs, language barriers, and cultural differences. By contrast, we are seeing steadily growing medical manufacturing markets in Costa Rica and Puerto Rico.